- Oct 01, 2018 - Sep 01, 2022
- Jose Muñoz
- Funded by
- EDCTP (European & Developing Countries Clinical Trial Partnership)
The current World Health Organization (WHO) control strategy for Soil-Transmitted Helminths (STH) emphasizes morbidity control through mass drug administration with albendazole or mebendazole, mainly targeting preschool and school-aged children in endemic areas. Increasing concerns have been raised about the success of these monotherapy strategies: 1) whilst albendazole is still efficacious against Ascaris lumbricoides and hookworm, a low and decreasing efficacy against Trichuris trichiura is observed, and none of these strategies is effective against Strongyloides stercoralis; 2) the use of widespread monotherapy could lead to the emergence of albendazole resistance. Modeling studies predict a huge impact on years lived with disability and economic productivity, if these strategies remain unchanged.
Ivermectin has shown an enhanced activity against T. trichiura when combined with albendazole, and is considered the drug of choice against strongyloidiasis and other parasitic infections. Adding ivermectin to albendazole would increase efficacy of the interventions, and decrease the possibility of emergence of resistance, as recently suggested by WHO.
The main goal of the STOP project is to develop and test the safety and efficacy of a fixed-dose co-formulation of ivermectin and albendazole against STHs, as a single dose and a three-dose regimen, compared to a single dose of albendazole in a phase III clinical trial.
The project will include capacity building and networking activities. Besides microscopy-based procedures, parasite DNA detecting techniques (PCR) will be used and validated as markers of treatment response. Modeling studies will evaluate the potential impact on transmission and economic benefits of the new treatment regimen. The scientific results will be presented to the scientific community, local governments and other implementation actors and stakeholders.
Previous collaborations of members of this consortium developed and tested the safety of a fixed high dose of ivermectin, as a first step towards the fixed-dose combination with albendazole. This consortium integrates complementary expertise in drug development, manufacture and regulatory processes with a pharmaceutical company, with expertise in parasitology, veterinary, epidemiology and public health. This places us in a unique situation to progress to the regulatory approval and market authorization by health authorities (WHO and EMA) and to advocate for policy changes among the different stakeholders, while ensuring a continuous supply of ivermectin for the control of several Neglected Tropical Diseases.
The proposed fixed-dose formulation represents a promising tool to alleviate the burden of STH morbidity, help stop STH transmission and ultimately contribute to the achievement of the SDGs.
Other projectsSee Past Projects
New Tools for the Diagnosis and Evaluation of Chagas Disease
Control of Leishmaniasis. From bench to bedside and community
Grup de recerca en patología importada i malaties emergents i re-emergents
Investigación aplicada al diagnóstico y tratamiento de los virus Zika, Dengue y Chikunguña
Antigen-specific immunological biomarkers associated to control of infection by T. cruzi.
Model and Tool for designing strategies to scale up Chagas Disease care
New chemotherapy regimens and biomarkers for Chagas Disease
Improving health data collection under the healthcare programme for migrant population in Nador, Morocco
Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.
Field validation of Trypanosoma cruzi-LAMP: a molecular point-of-care test for the control of congenital Chagas disease
Enhanced and equitable coverage of COVID-19 testing and treatment in Bolivia and Paraguay